These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36991239)

  • 21. Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study 'TOPICS Greece'.
    Efthimios D; Georgios K; Antonia A; Rania G; Maria-Eleutheria E;
    Clin Drug Investig; 2021 Oct; 41(10):865-874. PubMed ID: 34427893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.
    Berek K; Paganini C; Hegen H; Bsteh G; Grams A; Auer M; Berger T; Deisenhammer F; Di Pauli F
    Wien Med Wochenschr; 2022 Nov; 172(15-16):373-378. PubMed ID: 35142953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natalizumab-induced acquired perforating dermatosis.
    Fisher RM; Hadley G; Ieremia E; Moswela O; Zaki F; DeLuca GC; McPherson T
    Clin Exp Dermatol; 2021 Oct; 46(7):1373-1375. PubMed ID: 34086353
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.
    Manouchehrinia A; Larsson H; Karim ME; Lycke J; Olsson T; Kockum I
    Mult Scler; 2023 Apr; 29(4-5):628-636. PubMed ID: 36789885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic drug monitoring of natalizumab.
    Tanaka M
    Mult Scler; 2019 Oct; 25(12):1689-1690. PubMed ID: 30485149
    [No Abstract]   [Full Text] [Related]  

  • 27. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.
    Moccia M; Loperto I; Santoni L; Masera S; Affinito G; Carotenuto A; Lanzillo R; Triassi M; Morra VB; Palladino R
    Neurodegener Dis Manag; 2022 Jun; 12(3):109-116. PubMed ID: 35446149
    [No Abstract]   [Full Text] [Related]  

  • 28. [Natalizumab can induce progressive multifocal leucoencephalopathy].
    Theódórsdóttir A; Blaabjerg M; Falah M
    Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.
    Dobson R; Chung K
    Mult Scler; 2022 Feb; 28(2):326-327. PubMed ID: 35083940
    [No Abstract]   [Full Text] [Related]  

  • 30. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.
    Lo Buono V; D'Aleo G; Cammaroto S; De Cola MC; Palmese F; Smorto C; Marino S; Venuti G; Sessa E; Rifici C; Corallo F
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
    Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
    [No Abstract]   [Full Text] [Related]  

  • 33. Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
    Levin SN; Ezuma C; Levine L; Vargas WS; Farber RS; De Jager PL; Riley CS
    Mult Scler; 2020 Dec; 26(14):1964-1965. PubMed ID: 32552363
    [No Abstract]   [Full Text] [Related]  

  • 34. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
    J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
    Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
    Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma.
    Kaye AE; Hawkes ED; Gout II; El-Amir AN; Neffendorf JE
    Mult Scler Relat Disord; 2018 Nov; 26():74-76. PubMed ID: 30237107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
    Strijbis EM; Coerver E; Mostert J; van Kempen ZLE; Killestein J; Comtois J; Repovic P; Bowen JD; Cutter G; Koch M
    J Neurol Neurosurg Psychiatry; 2023 Oct; 94(10):792-799. PubMed ID: 37173129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
    Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship?
    Fama' F; Dattola V; Cicciu' M; Buccafusca M; Russo M; Lo Presti D; Dattilo G; Di Bella G
    Int J Cardiol; 2016 Mar; 206():127-8. PubMed ID: 26788687
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute Acalculous Cholecystitis in a Multiple Sclerosis Patient Treated with Natalizumab.
    Lambea-Gil A; Fumanal-Idocin L; Sebastián-Torres B; Saldaña-Inda I; Huici-Polo P; Alarcia-José-Ramon-Ramon Ara-Callizo R
    Neurol India; 2021; 69(2):495-496. PubMed ID: 33904486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.